Cosmo Pharmaceuticals Nv Stock Price Patterns
| CMOPF Stock | USD 138.19 5.31 3.70% |
Momentum 58
Buy Extended
Oversold | Overbought |
Using Cosmo Pharmaceuticals hype-based prediction, you can estimate the value of Cosmo Pharmaceuticals NV from the perspective of Cosmo Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Cosmo Pharmaceuticals to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Cosmo because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Cosmo Pharmaceuticals after-hype prediction price | USD 143.57 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Cosmo |
Cosmo Pharmaceuticals After-Hype Price Density Analysis
As far as predicting the price of Cosmo Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Cosmo Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Cosmo Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Cosmo Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Cosmo Pharmaceuticals' pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Cosmo Pharmaceuticals' historical news coverage. Cosmo Pharmaceuticals' after-hype downside and upside margins for the prediction period are 139.68 and 147.46, respectively. We have considered Cosmo Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Cosmo Pharmaceuticals is very steady at this time. Analysis and calculation of next after-hype price of Cosmo Pharmaceuticals is based on 3 months time horizon.
Cosmo Pharmaceuticals Pink Sheet Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Cosmo Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cosmo Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Cosmo Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.41 | 3.89 | 0.00 | 0.99 | 0 Events / Month | 1 Events / Month | In 5 to 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
138.19 | 143.57 | 0.05 |
|
Cosmo Pharmaceuticals Hype Timeline
Cosmo Pharmaceuticals is currently traded for 138.19. The entity stock is not elastic to its hype. The average elasticity to hype of competition is -0.99. Cosmo is projected to increase in value after the next headline, with the price projected to jump to 143.57 or above. The average volatility of media hype impact on the company the price is insignificant. The price rise on the next news is estimated to be 0.05%, whereas the daily expected return is currently at 0.41%. The volatility of related hype on Cosmo Pharmaceuticals is about 160.3%, with the expected price after the next announcement by competition of 137.20. The company reported the revenue of 65.07 M. Net Income was 21.67 M with profit before overhead, payroll, taxes, and interest of 32.1 M. Assuming the 90 days horizon the next projected press release will be in 5 to 10 days. Check out Cosmo Pharmaceuticals Basic Forecasting Models to cross-verify your projections.Cosmo Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Cosmo Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Cosmo Pharmaceuticals' future price movements. Getting to know how Cosmo Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Cosmo Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| BIOVF | Swedish Orphan Biovitrum | 0.00 | 0 per month | 0.00 | 0.15 | 1.06 | 0.00 | 3.80 | |
| BDULF | Bangkok Dusit Medical | 0.00 | 0 per month | 0.00 | 0.11 | 1.67 | 0.00 | 13.16 | |
| ERFSF | Eurofins Scientific SE | (7.28) | 4 per month | 2.39 | 0.04 | 5.80 | (4.24) | 13.70 |
Cosmo Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Cosmo price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Cosmo using various technical indicators. When you analyze Cosmo charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Cosmo Pharmaceuticals Predictive Indicators
The successful prediction of Cosmo Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Cosmo Pharmaceuticals NV, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Cosmo Pharmaceuticals based on analysis of Cosmo Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Cosmo Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Cosmo Pharmaceuticals's related companies.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Complementary Tools for Cosmo Pink Sheet analysis
When running Cosmo Pharmaceuticals' price analysis, check to measure Cosmo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cosmo Pharmaceuticals is operating at the current time. Most of Cosmo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cosmo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cosmo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cosmo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |